ÇÐȸ¼Ò½Ä

°øÁö»çÇ×

2014 Ãß°èÇмú´ëȸ Çмú»ó ¼ö»óÀÚ ¸í´Ü

±èÀº¿µ 2175 2014-12-02

<2014 Ãß°èÇмú´ëȸ Çмú»ó ¼ö»óÀÚ ¸í´Ü>



                 
  ±¸ºÐ Çмú»ó¸í ¸í¼ö ¼ö»óÀÚ ¼Ò¼Ó ÁÖ    Á¦ Çмú»ó±Ý  
  1 ¸í¹ÎÇмú»ó
ÃÖ¿ì¼ö³í¹®»ó
1¸í Á¦1ÀúÀÚ : ±ÇÅÃÁÖ
Ã¥ÀÓÀúÀÚ : Á¤ÁøÇâ
°æºÏÀÇ´ë °©»ó¼± À¯µÎ¾ÏÀÇ ¿¹ÈÄ ¿¹Ãø ÀÎÀڷμ­ BRAF V600E µ¹¿¬º¯ÀÌÀÇ ¿ªÇÒ  °¢ 50¸¸¿ø   
  2 ¸í¹ÎÇмú»ó
ÃÖ´Ù³í¹®»ó
1¸í Á¦1ÀúÀÚ : ³ª¾È¼ö
Ã¥ÀÓÀúÀÚ : À±ÇöÁ¶
ÀüºÏÀÇ´ë °©»ó¼± ÀüÀýÁ¦¼ú ÈÄ ÀúÄ®½·Ç÷ÁõÀ» ¿¹ÃøÇϱâ À§ÇÑ ºÎ°©»ó¼± È£¸£¸ó ¼öÄ¡  °¢ 50¸¸¿ø   
  3 ¸í¹ÎÇмú»ó
³í¹®Åõ°í»ó
4¸í Á¦1ÀúÀÚ : ¿ÀÀº¹Ì
Ã¥ÀÓÀúÀÚ : ÀÌ¿µµ·
°¡ÃµÀÇ´ë °©»ó¼± ÀüÀýÁ¦¼ú ÈÄ ¹ß»ýÇÑ ÀÏ°ú¼º ºÎ°©»ó¼±±â´ÉÀúÇÏÁõ ȯÀÚ ±º¿¡¼­
Á¶±â ȸº¹ ±ºÀÇ ÀÓ»ó Ư¡
 °¢ 50¸¸¿ø   
  Comparative Analysis of Three Lobectomy Methods for
Papillary Thyroid Cancer
 
  Á¦1ÀúÀÚ : ¼­¼öÇÑ
Ã¥ÀÓÀúÀÚ : ¼ÒÀÇ¿µ
Æ÷Ç×¼º¸ðº´¿ø °©»ó¼±¾Ï ȯÀÚ¿¡¼­ Ãø°æºÎ ¸²ÇÃÀý ÀüÀÌ¿©ºÎ Áø´Ü¿¡ ¼¼Ä§ÈíÀÔ¼¼Æ÷
°Ë»ç°¡ ¹ÏÀ»¸¸ÇÑ°¡?
 
  Á¦1ÀúÀÚ : °­¼ºÀÌ
Ã¥ÀÓÀúÀÚ : ±èµ¿ÁÖ
ÃæºÏÀÇ´ë µ¿¹ÝµÈ ¾ç¼º °©»ó¼± Áúȯ¿¡ µû¸¥ °©»ó¼± À¯µÎ¾ÏÀÇ ÀÓ»óº´¸®ÇÐÀû Ư¼º  
  Á¦1ÀúÀÚ : ±èö¼ö
Ã¥ÀÓÀúÀÚ : ±Ç¼ö°æ
°í½ÅÀÇ´ë ¼ö¼úÈÄ ºÎ°©»ó¼±¼±±â´ÉÀúÇÏÁõ ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ¿ìÀ¯-¾ËÄ®¸® ÁõÈıº   
  4 KABTS
¿ì¼ö¿¬Á¦¹ßÇ¥»ó
4¸í ¼­Çö¼® ¼­¿ïÀÇ´ë Elastic scattering for discrimination of benign from
mailgnant disease in thyroid nodules
 °¢ 50¸¸¿ø   
  ±è¼­±â ¼º±Õ°üÀÇ´ë Prediction table and nomogram as tools for diagnosis
of papillary thyroid carcinoma:
combined analysis of ultrasonography, fine needle aspiration biopsy,
and BRAF V600E mutation
 
  ±èÇü±Ô ¿¬¼¼ÀÇ´ë The incidence of cancer in thyroid nodules 4cm or larger
with preoperative FNAB benign cytology.
 
  Á¶Áø¼º Àü³²ÀÇ´ë Radioactive iodine therapy can be omitted in some intermediate risk
N1a Papillary throid cancer patients -
Especially on less than 50% of positive node ratio
 
  5 Çѹ̿ì¼öÆ÷½ºÅÍ»ó 2¸í ¼­¿ëÁØ ¼­¿ïÀÇ´ë Application of immunohistochemistry markers to classify thyroid neoplasm  °¢ 50¸¸¿ø   
  ±è¿ì¿µ °í·ÁÀÇ´ë Endoplasmic reticulum aminopeptidase 2 (ERAP2) is highly expressed
in papillary microcarcinoma with cervical lymph node metastasis